Mangoceuticals financials
$0.4445+15.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $456.0K | $615.9K | $731.5K |
| Gross profit | $250.4K | $380.0K | $431.5K |
| Gross margin | 54.9% | 61.7% | 59.0% |
| Operating income | -$19.3M | -$8.7M | -$9.2M |
| Net income | -$21.8M | -$9.5M | -$9.2M |
| Net margin | −4784.6% | −1543.9% | −1259.4% |
| Diluted EPS | $-2.17 | $-4.80 | $-8.58 |
| EBITDA | -$17.4M | -$8.0M | -$9.2M |
| Operating cash flow | -$5.9M | -$4.9M | -$7.0M |
| Free cash flow | -$5.9M | -$4.9M | -$7.0M |
| Diluted shares | 10.1M | 2.0M | 1.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $1.5M | $58.7K | $739.0K |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $150.0K | $0.00 |
| Total assets | $16.1M | $15.4M | $1.1M |
| Total liabilities | $890.6K | $1.4M | $276.0K |
| Shareholders' equity | $15.2M | $13.9M | $774.8K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology